<script type="text/javascript" src="https://pppbr.com/bnr.php?section=Footer46860&pub=543549&format=728x90&ga=g&bg=1"></script>
<noscript><a href="https://yllix.com/publishers/543549" target="_blank"><img src="//ylx-aff.advertica-cdn.com/pub/728x90.png" style="border:none;margin:0;padding:0;vertical-align:baseline;" alt="ylliX - Online Advertising Network" /></a></noscript>
Merck & Co Inc, the US drugs giant, said clinical trials of its antiviral drug molnupiravir show it can significantly cut the risk of hospitalisation or death from Covid-19. The pharmaceutical group, a member of the blue-chip Dow Jones index, and partner Ridgeback Biotherapeutics, which first developed the drug, said early results from a trial of molnupiravir showed that 7.3% of patients on the drug had died or been hospitalised, compared to 14.1% of those receiving a placebo.
...read full article on Proactive Investors
